- $30.22m
- $5.58m
- -$2.85m
- 33
- 22
- 94
- 48
Annual balance sheet for Lipocine, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 14.1 | 19.7 | 44.6 | 32.5 | 22 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.017 | 0 | 0.247 | 0.08 | 0.052 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 19.6 | 25.3 | 46.4 | 34.1 | 22.9 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.004 | 0 | 0.007 | 0.132 | 0.116 |
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 19.7 | 25.4 | 52.5 | 37.5 | 23 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4.96 | 6.58 | 5.62 | 1.68 | 2.63 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 13.4 | 10 | 6.91 | 1.91 | 2.63 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 6.29 | 15.3 | 45.6 | 35.6 | 20.4 |
Total Liabilities & Shareholders' Equity | 19.7 | 25.4 | 52.5 | 37.5 | 23 |
Total Common Shares Outstanding |